Ares Financial Consulting
GMAB icon

Ares Financial Consulting’s Genmab GMAB Stock Holding History

Ares Financial Consulting’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13K Hold
363
– – 0.01% 509
2026
Q2 		$10K Hold
363
– – 0.01% 565
2026
Q1 		$9.9K Buy
+363
New +$10.9K 0.01% 550

Other funds holding GMAB

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Perpetual Ltd
Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return
Oppenheimer Asset Management
Oppenheimer Asset Management New York $9.5B AUM 23.46% 1-Year Est. Return
Eagle Global Advisors
Eagle Global Advisors Houston, Texas $3.02B AUM 27.86% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
IMC Chicago
IMC Chicago Chicago, Illinois $483B AUM 41.26% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Ares Financial Consulting's GMAB Position: Q3 2026 in Review

Ares Financial Consulting held its Genmab (GMAB) position steady in Q3 2026 at 363 shares worth $13K. The position accounts for 0.01% of the portfolio, ranked #509.

Ares Financial Consulting first reported a position in GMAB in Q1 2026 and has held it in 3 quarters since. 137 funds tracked by Wall St. Rank hold GMAB as of Q3 2026.

  • Ares Financial Consulting held 363 shares of Genmab worth $13K as of Q3 2026.
  • Ares Financial Consulting left its Genmab share count unchanged in Q3 2026.
  • Genmab made up 0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #509 holding.
  • Ares Financial Consulting first reported a position in Genmab in Q1 2026 and has held it in 3 quarters since.
  • 137 funds tracked by Wall St. Rank held Genmab as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.